(Total Views: 370)
Posted On: 03/12/2018 8:20:18 PM
Post# of 30038
Re: All Aboard #26232
First changed noticed of Feb. 26 PR.
Noticed someone just updated the Board Information page. What's going on
Here's also a subtle change.
MARCH 08, 2018 - Elto Pharma Receives Notice of Allowance in Australia for Patent Covering Eltoprazine in the Treatment of Parkinson's Levodopa-induced Dyskinesia
https://www.amarantus.com/news/press-releases...tralia-for
MARCH 05, 2018 - Elto Pharma to Present and Participate in Neuroscience Panel at Sachs BioCapital USA Forum
https://ir.amarantus.com/press-releases/detai...uroscience
FEBRUARY 26, 2018
Amarantus Enters into Definitive Agreements for up to $1.5 Million in Funding
Noticed someone just updated the Board Information page. What's going on
Here's also a subtle change.
MARCH 08, 2018 - Elto Pharma Receives Notice of Allowance in Australia for Patent Covering Eltoprazine in the Treatment of Parkinson's Levodopa-induced Dyskinesia
Quote:
Elto Pharma is in the process of recruiting seasoned management to lead Elto Pharma going forward .
https://www.amarantus.com/news/press-releases...tralia-for
MARCH 05, 2018 - Elto Pharma to Present and Participate in Neuroscience Panel at Sachs BioCapital USA Forum
Quote:
"Sachs BioCapital USA Forum is an ideal venue for Elto Pharma to engage with the investment and partnering community," said Gerald Commissiong, interim-CEO of Elto Pharma .
https://ir.amarantus.com/press-releases/detai...uroscience
FEBRUARY 26, 2018
Amarantus Enters into Definitive Agreements for up to $1.5 Million in Funding
Quote:
"Concurrent with this announcement, the Company's CEO will be presenting an overview of Elto Pharma's pending Phase 2b Eltoprazine program for Parkinson's disease levodopa-induced dyskinesia (PD-LID) and Cutanogen Corporation's pending pivotal trial in Pediatric Severe Burns on Thursday March 1st, 2018 at 9:45pa ET at the BIOCOM Global Life Science Partnering Conference in San Diego, CA."
(3)
(0)Scroll down for more posts ▼
